| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -20,161 | -12,612 |
| Stock-based compensation | 94 | 17 |
| Depreciation and amortization | 159 | 110 |
| Prepaid expenses and other current assets | -357 | -274 |
| Operating lease right-of-use asset | 426 | 278 |
| Accounts payable, accrued compensation and other liabilities | -591 | -1,315 |
| Long-term operating lease liability | -640 | -420 |
| Net cash used in operating activities | -20,356 | -13,668 |
| Proceeds from issuance of common stock and pre-funded warrants exercise, net of issuance costs | - | 14,364 |
| Proceeds from issuance of common stock, pre-funded warrants exercise, and common warrants exercise, net of issuance costs | 32,703 | - |
| Net cash used in financing activities | 32,703 | 14,364 |
| Increase (decrease) in cash and cash equivalents | 12,347 | 696 |
| Cash and cash equivalents at beginning of period | 8,714 | - |
| Cash and cash equivalents at end of period | 21,061 | - |
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. (APVO)